Treatment landscape of metastatic pancreatic cancer.

摘要: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a dismal prognosis. The lack symptoms in the early phase disease makes diagnosis challenging, and about 80-85% patients are diagnosed only after locally advanced or metastatic. current front-line treatment landscape local stages comprises surgical resection adjuvant chemotherapy. In Switzerland, although both FOLFIRINOX gemcitabine plus nab-paclitaxel regimens feasible comparable first-line setting, preferred fit (Eastern Cooperative Oncology Group [ECOG] performance status [PS]: 0-1), young (<65 years old) few comorbidities normal liver function, while used to treat less (ECOG PS: 1-2) more vulnerable patients. second-line setting PDAC, there currently one approved regimen, based on III NAPOLI-1 trial. Furthermore, use liposomal-irinotecan second line supported by real-world data. Beyond standard care, various alternative modalities being explored clinical studies. Immunotherapy has demonstrated limited benefits until now, cases high microsatellite instability (MSI-H). However, data benefit poly (ADP-ribose) polymerase (PARP) inhibition as maintenance therapy germline BRCA-mutated tumors might signal advance targeted therapy. Currently, molecular genetic biomarkers for optimal stratification guiding decisions. Thus, identification predictive prognostic evaluating novel strategies equally relevant improving prognosis metastatic pancreatic